Affordable Access

[Long-term therapy of cancer pain. A controlled study on buprenorphine].

Authors
  • Zenz, M
  • Piepenbrock, S
  • Tryba, M
  • Glocke, M
  • Everlien, M
  • Klauke, W
Type
Published Article
Journal
Deutsche medizinische Wochenschrift (1946)
Publication Date
Mar 22, 1985
Volume
110
Issue
12
Pages
448–453
Identifiers
PMID: 2579784
Source
Medline
License
Unknown

Abstract

Sublingual tablets of buprenorphine (Temgesic sublingual) were given in a controlled trial of 41 patients for 2804 patient-days. With a mean starting dose of 1.09 mg and a final dose of 1.53 mg buprenorphine daily there was a good pain-relieving effect. The interval between doses was six to eight hours. The trial did not reveal any direct pointers as to tolerance or addictiveness after long-term intake of the drug. Because of its effectiveness and good duration of action, as well as the absence of negative long-term effects, the drug can be recommended in the long-term management of cancer pain.

Report this publication

Statistics

Seen <100 times